Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2014

01-07-2014 | Review

Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development

Authors: Juliana Inês Santos, Ana Luísa Teixeira, Francisca Dias, Mónica Gomes, Augusto Nogueira, Joana Assis, Rui Medeiros

Published in: Tumor Biology | Issue 7/2014

Login to get access

Abstract

In developed countries, prostate cancer (PC) is the neoplasia more frequently diagnosed in men. The signaling pathway induced by the transforming growth factor β1 (TGFβ1) has an important role in cell growth, differentiation, and development, the downregulation of this pathway being associated with cancer development. In PC, the activation of this signaling pathway is lost, resulting in favoring of tumor growth, proliferation, and evasion of apoptosis. Several studies have shown that microRNAs (miRNAs), small non-coding RNA, are closely associated with the development, invasion, and metastasis, suggesting that they have a critical role in cancer development. Recently, Smad proteins, the signal transducers of the TGFβ1 signaling pathway, were found to regulate miRNA expression, through both transcriptional and posttranscriptional mechanisms. In this review, we summarize the mechanisms underlying Smad-mediated regulation of miRNA biogenesis and the effects on cancer development, particularly in PC. We identify that TGFβ1-related miR-143, miR-145, miR-146a, and miR-199a may have a key role in the development of prostate cancer metastasis and the restoration of their expression may be a promising therapeutic strategy for PC treatment.
Literature
1.
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.CrossRefPubMed
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
3.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.CrossRefPubMed
4.
Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets. 2012;13:1308–23.PubMedCentralCrossRefPubMed
5.
Kumar V, Cotran R, Collins T. Robbins and Cotran pathologic basis of disease, ed 7. 2005.
6.
Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate cancer and breast cancer and the risk of prostate cancer in the PSA era. Prostate. 2008;68:1582–91.PubMedCentralCrossRefPubMed
7.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.CrossRefPubMed
8.
Houlgatte A, Vincendeau S, Desfemmes F, Ramirez J, Benoist N, Bensalah K, et al. Use of [-2] pro PSA and phi index for early detection of prostate cancer: A prospective of 452 patients. Prog Urol J Assoc Fr Urol Soc Fr Urol. 2012;22:279–83.
9.
Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem. 2013;59:306–14.CrossRefPubMed
10.
Zhang J, Zhao H, Gao Y, Zhang W. Secretory miRNAs as novel cancer biomarkers. Biochim Biophys Acta. 1826;2012:32–43.
11.
Hao Y, Zhao Y, Zhao X, He C, Pang X, Wu TC, et al. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Investig. 2011;29:318–24.CrossRef
12.
Fontenete S, Silva J, Teixeira AL, Ribeiro R, Bastos E, Pina F, et al. Controversies in using urine samples for prostate cancer detection: PSA and PCA3 expression analysis. Int Braz J Urol Off J Braz Soc Urol. 2011;37:719–26.CrossRef
13.
Nam RK, Zhang W, Siminovitch K, Shlien A, Kattan MW, Klotz LH, et al. New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther. 2011;12:997–1004.PubMedCentralCrossRefPubMed
14.
Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, et al. Cxcl12 g801a polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 2007;13:5056–62.CrossRefPubMed
15.
Wang SK, Wang ZZ, Huang YF. [Advances in researches on the relationship between single nucleotide polymorphism and prostate cancer]. Zhonghua nan ke xue =. Natl J Androl. 2005;11:605–10.
16.
Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71:326–31.CrossRefPubMed
17.
18.
Nicolas Mottet JB. Michel Bolla, Steven Joniau, Malcolm Masone, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.CrossRefPubMed
19.
Silva FCd (ed) Recomendações clínicas no tratamento do carcinoma da próstata, Lisboa, 2013, pp 226.
20.
Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011;57:1366–75.CrossRefPubMed
21.
Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009;15:3251–5.CrossRefPubMed
22.
Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.CrossRefPubMed
23.
Kavleen Sikand SB, Girish C. Shukla. MicroRNAs and androgen receptor 3′ untranslated region: a missing link in castration-resistant prostate cancer? Mol Cell Pharmacol. 2011;3:107–13.PubMedCentralPubMed
24.
Keith F. Decker DZ, Yuhong He, Tamara Bowman, John R. Edwards and Li Jia. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res. 2012:1–15.
25.
26.
Myles C, Hodgson IA, Anthony N. Hollenberg. Prostate cancer cells is independent of NCoR and SMRT activity of androgen receptor antagonist bicalutamide in corepressors. Cancer Res. 2007;67:8388–95.CrossRef
27.
Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer. 2012;2012:327253.PubMedCentralCrossRefPubMed
28.
Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res. 2006;12:1665–71.CrossRefPubMed
29.
Sen A, De Castro I, Defranco DB, Deng FM, Melamed J, Kapur P, et al. Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest. 2012;122:2469–81.PubMedCentralCrossRefPubMed
30.
Zhu B, Kyprianou N. Transforming growth factor beta and prostate cancer. Cancer Treat Res. 2005;126:157–73.CrossRefPubMed
31.
Rojas A, Padidam M, Cress D, Grady WM. TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. Biochim Biophys Acta. 2009;1793:1165–73.PubMedCentralCrossRefPubMed
32.
Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis. 2004;25:237–40.CrossRefPubMed
33.
Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech. 2001;52:411–9.CrossRefPubMed
34.
35.
36.
37.
38.
Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1(+) myeloid cells and facilitate liver metastasis. Gastroenterology. 2013;145:1064–75. e1011.CrossRefPubMed
39.
Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73:725–35.CrossRefPubMed
40.
Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer. 2007;7:156.PubMedCentralCrossRefPubMed
41.
Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, et al. The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest. 2007;117:206–17.PubMedCentralCrossRefPubMed
42.
43.
Teixeira AL, Gomes M, Nogueira A, Azevedo AS, Assis J, Dias F, et al. Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFbeta1 signaling pathway modulation. PLoS One. 2013;8:e72419.PubMedCentralCrossRefPubMed
44.
Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev. 2000;11:159–68.CrossRefPubMed
45.
Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 1998;37:19–29.CrossRefPubMed
46.
Butz H, Racz K, Hunyady L, Patocs A. Crosstalk between TGF-beta signaling and the microRNA machinery. Trends Pharmacol Sci. 2012;33:382–93.CrossRefPubMed
47.
48.
Hata A, Davis BN. Control of microRNA biogenesis by TGFbeta signaling pathway-a novel role of Smads in the nucleus. Cytokine Growth Factor Rev. 2009;20:517–21.PubMedCentralCrossRefPubMed
49.
Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell. 2010;39:373–84.PubMedCentralCrossRefPubMed
50.
Long X, Miano JM. Transforming growth factor-beta1 (TGF-beta1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem. 2011;286:30119–29.PubMedCentralCrossRefPubMed
51.
Ma S, Chan YP, Kwan PS, Lee TK, Yan M, Tang KH, et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 2011;71:583–92.CrossRefPubMed
52.
Shi XB, Tepper CG. deVere White RW. Cancerous miRNAs and their regulation. Cell Cycle. 2008;7:1529–38.CrossRefPubMed
53.
Sk A. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors. 2012;12:3359–69.CrossRef
54.
Vasudevan S. Posttranscriptional upregulation by microRNAs. Wiley Interdiscip Rev RNA. 2012;3:311–30.CrossRefPubMed
55.
56.
Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, Mauricio J, Lobo F, Medeiros R. Higher circulating expression levels of mir-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013.
57.
58.
Davis BN, Hata A. Regulation of microRNA biogenesis: a miRiad of mechanisms. Cell Commun Signal CCS. 2009;7:18.CrossRefPubMed
59.
60.
McDonald RA, Hata A, MacLean MR, Morrell NW, Baker AH. MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovasc Res. 2012;93:594–604.PubMedCentralCrossRefPubMed
61.
Bowen T, Jenkins RH, Fraser DJ. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol. 2013;229:274–85.CrossRefPubMed
62.
Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28:6773–84.PubMedCentralCrossRefPubMed
63.
Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, et al. TGF-beta activates akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11:881–9.PubMedCentralCrossRefPubMed
64.
Kato M, Wang L, Putta S, Wang M, Yuan H, Sun G, et al. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem. 2010;285:34004–15.PubMedCentralCrossRefPubMed
65.
Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, et al. miR-200a prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes. 2011;60:280–7.PubMedCentralCrossRefPubMed
66.
Dogar AM, Towbin H, Hall J. Suppression of latent transforming growth factor (TGF)-beta1 restores growth inhibitory TGF-beta signaling through microRNAs. J Biol Chem. 2011;286:16447–58.PubMedCentralCrossRefPubMed
67.
Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22:894–907.PubMedCentralCrossRefPubMed
68.
Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 2008;5:115–9.PubMedCentralCrossRefPubMed
69.
Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G, et al. Down-regulation of Kruppel-like factor-4 (klf4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem. 2011;286:28097–110.PubMedCentralCrossRefPubMed
70.
Jurkin J, Schichl YM, Koeffel R, Bauer T, Richter S, Konradi S, et al. miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation. J Immunol. 2010;184:4955–65.CrossRefPubMed
71.
Bello-DeOcampo D, Tindall DJ. TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets. 2003;4:197–207.CrossRefPubMed
72.
Paolo Fuzio PD. Monica Rutigliano, Michele Battaglia, et al. Regulation of TGF-b1 expression by androgen deprivation therapy of prostate cancer. Cancer Lett. 2012;318:135–44.CrossRefPubMed
73.
Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F. microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010;24:1363–9.PubMed
74.
Akao Y, Nakagawa Y, Iio A, Naoe T. Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk Res. 2009;33:1530–8.CrossRefPubMed
75.
Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460:705–10.PubMedCentralPubMed
76.
Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28:1385–92.CrossRefPubMed
77.
Ni Y, Meng L, Wang L, Dong W, Shen H, Wang G, et al. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene. 2013;517:197–204.CrossRefPubMed
78.
Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38:1093–101.PubMed
79.
Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Molecular Cancer Res MCR. 2010;8:529–38.CrossRefPubMed
80.
Yin Y, Yan ZP, Lu NN, Xu Q, He J, Qian X, et al. Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochim Biophys Acta. 1829;2013:239–47.
81.
82.
Lo U-G, Yang D, Hsieh J-T. The role of microRNAs in prostate cancer progression. Transl Androl Urol. 2013;2:228–41.
83.
84.
Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, et al. Mir-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate. 2012;72:1171–8.CrossRefPubMed
85.
Zhang J, Zhang D, Wu GQ, Feng ZY, Zhu SM. Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. Hepatobiliary Pancreat Dis Int. 2013;12:305–9.
86.
Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007;38:1547–52.CrossRefPubMed
87.
88.
89.
Carrion-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, et al. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative her receptors and ligands. Int J Oncol. 2012;41:1128–38.PubMed
90.
Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ, Park ES, et al. Correlation of AR, EGFR, and HER2 expression levels in prostate cancer: immunohistochemical analysis and chromogenic in situ hybridization. Cancer Res Treat Off J Korean Cancer Assoc. 2012;44:50–6.
91.
Wu D, Huang HJ, He CN, Wang KY. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR). Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2013;23:1191–7.CrossRef
92.
Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. Mir-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–93.CrossRefPubMed
Metadata
Title
Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development
Authors
Juliana Inês Santos
Ana Luísa Teixeira
Francisca Dias
Mónica Gomes
Augusto Nogueira
Joana Assis
Rui Medeiros
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1887-z

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue

Research Article

High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy

Research Article

Expression of basic fibroblast growth factor, CD31, and α-smooth muscle actin and esophageal cancer recurrence after definitive chemoradiation

Research Article

Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis

Research Article

Association of a genetic variant in microRNA-146a with risk of colorectal cancer: a population-based case-control study

Research Article

N-Acetyltransferase 2 status and gastric cancer risk: a meta-analysis

Research Article

Mir-302 cluster exhibits tumor suppressor properties on human unrestricted somatic stem cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits